Articles

Archive by author: Howard FienbergReturn
Based in Washington, DC, Howard is the Insights Association's lobbyist for the marketing research and data analytics industry, focusing primarily on consumer privacy and data security, the Telephone Consumer Protection Act (TCPA), tort reform, and the funding and integrity of the decennial Census and the American Community Survey (ACS). Howard has more than two decades of public policy experience. Before the Insights Association, he worked in Congress as senior legislative staffer for then-Representatives Christopher Cox (CA-48) and Cliff Stearns (FL-06). He also served more than four years with a science policy think tank, working to improve the understanding of scientific and social research and methodology among journalists and policymakers. Howard is also co-director of The Census Project, a 900+ member coalition in support of a fair and accurate Census and ACS. He has also served previously on the Board of Directors for the National Institute for Lobbying and Ethics and and the Association of Government Relations Professionals. Howard has an MA International Relations from the University of Essex in England and a BA Honors Political Studies from Trent University in Canada, and has obtained the Certified Association Executive (CAE), Professional Lobbying Certificate (PLC) and the Public Policy Certificate (PPC). When not running advocacy for the Insights Association, Howard enjoys hockey, NFL football, sci-fi and horror movies, playing with his dog, and spending time with family and friends.
Virginia Governor Ralph Northam (D) signed comprehensive privacy legislation, the Virginia Consumer Data Protection Act (CDPA), into law on March 2, 2021. The new law emulates aspects of the California Consumer Privacy Act (CCPA) and the EU General Data Protection Regulation (GDPR).
Read More
Pennsylvania Rep. Mike Zabel (D-PA-163) reintroduced the Pharmaceutical Manufacturing Prohibited Gifts Act (H.B. 593), adding an amendment recommended by the Insights Association that would protect bona fide marketing research with health care professionals.
Read More
"Businesses expose themselves and their customers to heightened risk when they share sensitive data with firms located" in the People's Republic of China, "or use equipment and software developed by firms with an ownership nexus in the PRC, as well as with firms that have PRC citizens in key leadership and security-focused roles," especially for "data service providers and data infrastructure,” according to a new business advisory from the U.S. Department of Homelan...
Read More
The Insights Association today called upon its members and all organizations operating in the market research and data analytics space during this time of economic tumult to forgo enforcement of noncompete agreements for staff involuntarily separated from their organizations without full compensation.
Read More
How should the U.S. insights industry approach the “iron triangle” of employment agreements – Non-Competes, Non-Disclosures and Non-Solicits – especially during the COVID-19 crisis?
Read More
The Office of Management and Budget’s Chief Statistician, Nancy Potok, recently assured the Insights Association that any government reorganization of statistical agencies involving the Census Bureau will not occur until after the 2020 Census, as we had requested.
Read More
The White House's recent proposal to reorganize the federal government included a provision of intense interest to the marketing research and data analytics industry: the consolidation of the biggest federal statistical agencies. However, the Insights Association today urged the Trump Administration and Congress to delay any consolidation plans until after the 2020 Census.
Read More
Companies who need to access the national number portability database include marketing research companies.
Read More
Are all people who need to access the national number portability database "telemarketers?"
Read More
On August 1, 2013, the first reporting period under the Physician Payment Sunshine Act began. Part of the Patient Protection and Affordable Care Act (aka, “Obamacare”), it requires pharmaceutical and medical device manufacturers to publicly report many types of payments made to physicians, which will be public. The Sunshine Act was intended to bring transparency to these relationships, to minimize manufacturers’ influence on physicians’ prescribing behavior.
Read More
Page 4 of 10 [4]
Members only Article - Please login to view